ArticleTheranostics2020
Coating biomimetic nanoparticles with chimeric antigen receptor T cell-membrane provides high specificity for hepatocellular carcinoma photothermal therapy treatment.
Article in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
114 citing papers in PubMed, 2 syntheses or guidelines pooled it, 226 citations in OpenAlex.
- Nanoparticles based on photothermal effects in the treatment of hepatocellular carcinoma (HCC): a meta-analysis and systematic review.BMC cancer · 2026Pooled it
- Pooled it
- Precisely Engineering Biomimetic Nanoparticles via Controlled Cell Membrane Coating.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Engineered Cell Membrane-Coated Nanoparticles: A New Strategy for Pancreatic Cancer Therapy.ACS pharmacology & translational science · 2026Review
- Nanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Nanomaterials: An innovative integrative paradigm for hepatocellular carcinoma adjuvant treatment.Asian journal of pharmaceutical sciences · 2026Review
- Engineered cell-biomimetic nanosystems for anti-inflammatory therapy: Targeting, neutralization and immunomodulation.Acta pharmaceutica Sinica. B · 2026Review
- Nanotechnology-enhanced CAR-T therapy strategies in cancer, aging, and autoimmune diseases.Journal of hematology & oncology · 2026Review
- Advances in immune cell-based therapeutic agents for the treatment of inflammation-related diseases.Acta pharmaceutica Sinica. B · 2026Review
- T cell-inspired therapeutic delivery platforms: From nanomedicines to cell therapy.Materials today. Bio · 2026Review
- Membrane-derived biomimetic nanovesicles in anti-tumor immunotherapy: Advances and outlook.Acta pharmaceutica Sinica. B · 2026Review
- Nanoparticles-enhanced CAR-T cell therapy: current advances and future directions.Biomarker research · 2026Review
- Biomimetic nanoparticles in cancer photodynamic therapy: a review of targeted delivery systems and therapeutic outcomes.Beilstein journal of nanotechnology · 2026Review
- Membrane-modified mesoporous silica nanoparticles guided by tumor immunomodulatory regulation for anti-tumor strategies.Frontiers in immunology · 2026Review
- Genetically Engineered Cell Membrane-Coated Nanodrug for Targeted Treatment of Thyroid Cancer.Biomaterials research · 2026Article
- Integrating diagnosis and therapy in hepatocellular carcinoma: advances in nanotheranostics.Frontiers in bioengineering and biotechnology · 2026Review
- Immunocyte reprogramming empowers live-cell drug delivery: Mechanistic insights, delivery strategies, and clinical perspectives.Acta pharmaceutica Sinica. B · 2026Review
- Biomimetic Polymer-Based Nanomaterials for Immune-Responsive Hepatocellular Carcinoma Therapy.International journal of nanomedicine · 2026Review
- CAR Therapies: Ex Vivo and In Vivo Potential of Exosomes and Biomimetic Nanoparticles.Cancers · 2025Review
- Nanoparticle-based strategy in CAR-T cell immunotherapy: challenges, implications, and perspectives.Molecular cancer · 2025Review
54 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.